Investigation of the Status of Immune Checkpoint Molecules in Meningiomas by Immunohistochemistry

Saygın İ., Çakır E., Kazaz S. N., Güvercin A. R., Eyüboğlu İ., Ustaoglu M. M.

TURKISH NEUROSURGERY, vol.34, no.4, pp.647-654, 2024 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 4
  • Publication Date: 2024
  • Doi Number: 10.5137/1019-5149.jtn.43334-23.2
  • Journal Name: TURKISH NEUROSURGERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, MEDLINE
  • Page Numbers: pp.647-654
  • Keywords: CTLA-4, Immune checkpoint molecules, Immunotherapy, Meningioma, TIM-3
  • Karadeniz Technical University Affiliated: Yes

Abstract

AIM: To investigate the status of immune checkpoint molecules (CTLA-4 and TIM-3) in meningiomas and thus contribute to the development of new personalized treatment strategies. MATERIAL and METHODS: We utilized 402 cases of meningioma for this study. New blocks were prepared using the tissue microarray method, and sections obtained from these blocks were immunohistochemically stained with CTLA-4 and TIM-3 RESULTS: Our findings revealed that CTLA-4 expression were observed in 25.1% of meningiomas. CTLA-4 expression and the number of expressing lymphocytes were found to be significantly higher in high-grade tumors and in those with brain invasion. Meningiomas with staining of immune cells with TIM-3 are 3.5%, and the tumor grade was correlated with the number of immune CONCLUSION: Immune checkpoint molecules (CTLA-4 and TIM-3) with varying levels of expression can serve as prognostic and predictive biomarkers, as well as important targets for therapy. Drugs developed for CTLA-4 and TIM-3 molecules may prove to be more effective in treating meningiomas with high-grade, brain-invading, spontaneous necrosis, and macronucleolus.